RCUS
RCUS
NYSE · Biotechnology

Arcus Biosciences Inc

$17.92
-1.39 (-7.20%)
Financial Highlights (FY 2026)
Revenue
284.56M
Net Income
-406,685,200
Gross Margin
—
Profit Margin
-142.9%
Rev Growth
+30.2%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 44.4% 44.4%
Operating Margin -156.3% -140.7% -6.5% -6.4%
Profit Margin -142.9% -135.8% -8.0% -7.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 284.56M 218.62M 841.86M 875.48M
Gross Profit — — 374.19M 389.13M
Operating Income -444,711,707 -307,498,875 -54,514,708 -55,744,444
Net Income -406,685,200 -281,205,193 -67,570,170 -63,346,573
Gross Margin — — 44.4% 44.4%
Operating Margin -156.3% -140.7% -6.5% -6.4%
Profit Margin -142.9% -135.8% -8.0% -7.2%
Rev Growth +30.2% +30.2% +8.2% -1.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 154.30M 154.30M 401.69M 484.63M
Total Equity 983.42M 983.42M 1.67B 1.64B
D/E Ratio 0.16 0.16 0.24 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -433,176,408 -316,162,866 -58,220,570 -69,808,840
Free Cash Flow — — -41,442,789 -42,253,468